Cookies on this website

We use cookies to ensure that we give you the best experience on our website. If you click 'Accept all cookies' we'll assume that you are happy to receive all cookies and you won't see this message again. If you click 'Reject all non-essential cookies' only necessary cookies providing core functionality such as security, network management, and accessibility will be enabled. Click 'Find out more' for information on how to change your cookie settings.

The last seven years have seen the greatest surge of Ebola virus disease (EVD) cases in equatorial Africa, including the 2013-2016 epidemic in West Africa and the recent epidemics in the Democratic Republic of Congo (DRC). The vaccine clinical trials that took place in West Africa and the DRC, as well as follow-up studies in collaboration with EVD survivor communities, have for the first time allowed researchers to compare immune memory induced by natural infection and vaccination. These comparisons may be relevant to evaluate the putative effectiveness of vaccines and candidate medical countermeasures such as convalescent plasma transfer. In this study, we compared the long-term functionality of anti-EBOV glycoprotein (GP) antibodies from EVD survivors with that from volunteers who received the recombinant vesicular stomatitis virus vectored vaccine (rVSV-ZEBOV) during the Phase I clinical trial in Hamburg. Our study highlights important differences between EBOV vaccination and natural infection and provides a framework for comparison with other vaccine candidates.

Original publication

DOI

10.3390/v12090915

Type

Journal article

Journal

Viruses

Publication Date

08/2020

Volume

12

Addresses

Division of Infectious Diseases, 1st Department of Medicine, University Medical Center Hamburg-Eppendorf, 20251 Hamburg, Germany.

Keywords

Humans, Vesiculovirus, Hemorrhagic Fever, Ebola, Immunoglobulins, Viral Envelope Proteins, Ebola Vaccines, Antibodies, Viral, Vaccination, Viral Load, Immunologic Memory, Adult, Survivors, Female, Male, Ebolavirus, Antibodies, Neutralizing